---
layout: default
title: Fulvestrant
parent: Low Evidence (L5)
nav_order: 454
evidence_level: L5
indication_count: 10
---

# Fulvestrant
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Fulvestrant: From Hormone Receptor-Positive Breast Cancer to HIV Infectious Disease

## One-Sentence Summary

Fulvestrant is an injectable estrogen receptor antagonist and degrader, used for hormone receptor-positive advanced breast cancer.
The TxGNN model predicts it may be effective for **HIV infectious disease**, but this is **a model prediction only**, with **0 clinical trials** and **1 publication** (which concerns a different virus, HTLV-1).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Hormone receptor-positive advanced breast cancer (from general drug knowledge and the trial context; the HSA indication text was not supplied) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 8 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, fulvestrant is a selective estrogen receptor degrader (an ER antagonist). Its efficacy in hormone receptor-positive breast cancer is established.

There is no supported mechanistic link to HIV in the provided data, and fulvestrant has no known antiviral activity. The one publication found studies HTLV-1-associated myelopathy, a different retrovirus, and does not test fulvestrant in HIV. The very high score (0.999) most likely reflects knowledge-graph neighbours rather than pharmacological evidence. Similar predictions for simian immunodeficiency virus infection and feline immunodeficiency syndrome share the same score and appear to be redundant signals.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [40343334](https://pubmed.ncbi.nlm.nih.gov/40343334/) | 2025 | Cohort / cross-omics | Research Square | Multi-cohort systems biology analysis of HTLV-1-associated myelopathy, identifying disease mechanisms and therapeutic targets. It concerns HTLV-1, not HIV, and does not show fulvestrant efficacy. |

---

## Singapore Market Information

Eight registrations are on record; five are listed below. The approved indication text was not supplied for any of them.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| SIN16154P | Fulvestrant-Teva Solution for Injection 250mg/5ml | Injection, solution | — |
| SIN17045P | Fulvestrant Ever Pharma Solution for Injection in Pre-filled Syringe 250mg/5ml | Injection, solution | — |
| SIN16848P | Eranfu Fulvestrant Solution for Injection in Pre-filled Syringe 250mg/5ml | Injection, solution | — |
| SIN16152P | Fulvestrant Sandoz Solution for Injection in Prefilled-Syringe 250mg/5ml | Injection, solution | — |
| SIN16780P | Fulvestrant-AFT Solution for Injection in Prefilled-Syringe 250mg/5ml | Injection, solution | — |

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Endocrine (hormonal) therapy, a selective estrogen receptor degrader. It is not a conventional cytotoxic agent. |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HIV prediction has no clinical trials, no HIV-specific literature and no plausible mechanism in the provided data, so it stays at L5 (model prediction only).

**To proceed, the following is needed:**
- The HSA package insert (warnings, contraindications, approved indications), which is a blocking gap for safety screening
- Mechanism of action data from DrugBank
- Any preclinical evidence of fulvestrant activity against HIV. Without it, the prediction has no biological support.
- Screening of the other predicted indications:
  - **Multiple endocrine neoplasia:** the 10 trials shown are all ER+/HR+ breast cancer studies, so the remaining 40 should be checked for MEN-specific studies.
  - **Rheumatoid arthritis:** the evidence is indirect and points in mixed directions, so a hypothesis on the direction of effect is needed first.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

